Chembio Diagnostics Announces Agreement for Reszon Diagnostics International to Manufacture Chembio’s HIV 1/2 STAT-PAK Assay at Chembio Diagnostics Malaysia Facility
17 mai 2022 08h00 HE
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., May 17, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it...
Chembio Diagnostics Reports First Quarter 2022 Financial Results
05 mai 2022 16h05 HE
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., May 05, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases,...
Chembio Diagnostics to Report First Quarter 2022 Financial Results on May 5, 2022
21 avr. 2022 16h05 HE
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., April 21, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will...
Chembio Diagnostics Reports Fourth Quarter and Full Year 2021 Financial Results
03 mars 2022 16h05 HE
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., March 03, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases,...
Chembio Diagnostics to Report Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022
17 févr. 2022 16h05 HE
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will...
Chembio Diagnostics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
06 janv. 2022 16h05 HE
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today reported that, in...
Chembio Diagnostics Announces Appointment of Larry Steenvoorden as Chief Financial Officer
05 janv. 2022 16h05 HE
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the...
Chembio Diagnostics Submits FDA De Novo/510(k) Request for DPP SARS-CoV-2 Antigen Test System
06 déc. 2021 08h00 HE
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it has...
Chembio Diagnostics Receives SAHPRA Approval for DPP SARS-CoV-2 Antigen Test
29 nov. 2021 08h00 HE
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced receipt on...
Chembio Diagnostic Systems Prevails in International Arbitration Against BioSure (UK) Ltd
22 nov. 2021 08h00 HE
|
Chembio Diagnostics, Inc.
HAUPPAUGE, N.Y., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostic Systems Inc. (“Chembio”), a subsidiary of Chembio Diagnostics, Inc. (Nasdaq: CEMI), received an international arbitration award...